definiens: and the diseases or conditions within the, as such terms are definedin the Combination Product License Agreement, as follows . During the Exclusive Negotiation Period, ATHXwill not, and will cause its Affiliates not to, negotiate with any other person or entity the terms or conditions ofany license under any intellectual property rights of ATHX or its Affiliates to research, develop, manufacture, have manufactured, use, distribute, promote, sell, offer for sale, market, distribute, import, export orotherwise commercialize, anywhere in the world, any MultiStem product that is used in treatment of anydisease or condition in combination with iPSC - derived cells by either ( i ) non - systemic, localizedadministration of the MultiStem product at the same time and immediate vicinity as the iPSC - derived celltransplantation or ( ii ) as a combination formulation containing both the MultiStem product and iPSC - derivedcells, provided that the foregoing shall not preclude ATHX from negotiating with any other person or entitythe terms or conditions of any license to manufacture or have manufactured any standalone MultiStemproducts ( i.e